drugset / Trial / NCT01960010

A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

NCT01960010 ↗

Phase 3 Completed 403 enrolled Mimetogen Pharmaceuticals USA, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of MIM-D3 Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Timeline

Start
2013-10
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tavilermide Protein / enzyme biologic 1 % —

Indications